UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000015551
Receipt number R000018070
Scientific Title Study of galectin-9 as novel biomarker of activity and therapeutic agent in IgA nephropathy
Date of disclosure of the study information 2014/11/11
Last modified on 2019/11/13 20:04:45

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study of galectin-9 as novel biomarker of activity and therapeutic agent in IgA nephropathy

Acronym

Study of galectin-9 as novel biomarker of activity and therapeutic agent in IgA nephropathy

Scientific Title

Study of galectin-9 as novel biomarker of activity and therapeutic agent in IgA nephropathy

Scientific Title:Acronym

Study of galectin-9 as novel biomarker of activity and therapeutic agent in IgA nephropathy

Region

Japan


Condition

Condition

IgA nephropathy

Classification by specialty

Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Prognosis value of plasma and urinary galectin-9 concentrations for activity and treatment reactivity of patient with IgA nephropathy

Basic objectives2

Others

Basic objectives -Others

disease activity of IgA nephropathy

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Urinary protein, hematuria, serum creatinine, estimated GFR, histological findings

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

Patients who have been diagnosed with IgA nephropathy by renal biopsy
Patients who will receive the tonsillectomy and steroid therapy.
Patients who agree to participate in the study.

Key exclusion criteria

Patients under age 16 and over 80.
Patients who do not agree to participate in the study.
Patients decided by the doctor to be unsuitable to the study other than above.

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Masahiro
Middle name
Last name Moritoki

Organization

Kagawa University Hospital

Division name

Department of nephrology

Zip code

761-0793

Address

1750-1 Ikenobe, Mikityou, Kitagun, Kagawa-ken JAPAN

TEL

087-891-2149

Email

moritoki@med.kagawa-u.ac.jp


Public contact

Name of contact person

1st name Masahiro
Middle name
Last name Moritoki

Organization

Kagawa University Hospital

Division name

Department of nephrology

Zip code

761-0793

Address

1750-1 Ikenobe, Mikityou, Kitagun, Kagawa-ken JAPAN

TEL

087-891-2149

Homepage URL


Email

moritoki@med.kagawa-u.ac.jp


Sponsor or person

Institute

Kagawa University Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kagawa University School of Medicine Ethics Committee

Address

1750-1 Ikenobe, Mikityou, Kitagun, Kagawa-ken JAPAN

Tel

087-898-5111

Email

chiken-b.@med.kagawa-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 11 Month 11 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2014 Year 10 Month 29 Day

Date of IRB

2014 Year 10 Month 29 Day

Anticipated trial start date

2014 Year 11 Month 01 Day

Last follow-up date

2022 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Prospective cohort study
Predictive variable: galectin-9
Outcome: disease activity and treatment reactivity of IgA nephropathy


Management information

Registered date

2014 Year 10 Month 28 Day

Last modified on

2019 Year 11 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018070


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name